Orphan Technologies starts OT-58 trial for homocystinuria treatment breakthrough
Swiss pharmaceutical company Orphan Technologies has begun dosing patients in a Phase 1/2 trial (CBS-HCY-01) to assess the…
EMD Serono facility expansion in Massachusetts set to advance immuno-oncology research
German pharmaceutical giant Merck KGaA has announced a significant investment of $70 million to expand its EMD Serono…
Merck to invest $70m in expansion of US biopharma facility
German pharmaceutical giant Merck is set to invest $70 million to expand its EMD Serono research and development…
Fresenius Kabi launches Methocarbamol Injection in US for acute musculoskeletal conditions
Fresenius Kabi, the global German healthcare company, has unveiled Methocarbamol Injection, USP in the United States, marking a…
Novus Therapeutics begins phase 1 trial of OP0201 in otitis media
Novus Therapeutics has launched a phase 1 pharmacodynamics clinical trial for its promising candidate, OP0201, aimed at treating…
EC approves ADCETRIS for treating CD30+ Stage IV Hodgkin lymphoma
The European Commission (EC) has officially expanded the approval of Takeda Pharmaceutical’s ADCETRIS (brentuximab vedotin) to include the…
Dr. Henry’s Vitamins reveals game-changing Prenatal Plus and Omega-3 for Women
Dr. Henry’s Vitamins has unveiled its latest product offerings: the Prenatal Plus and Omega-3 for Women, crafted with…
Samsung Bioepis partners with C-Bridge Capital to expand biosimilar portfolio in China
Samsung Bioepis, a South Korean leader in biopharmaceuticals, has struck a deal with private equity firm C-Bridge Capital…
Ablynx secures FDA approval for Cablivi to treat aTTP
In a significant milestone for Belgian biopharma company Ablynx, the U.S. Food and Drug Administration (FDA) has granted…
Pulmazole phase 2 clinical study gets FDA approval for Pulmazole in allergic bronchopulmonary aspergillosis
Pulmatrix, the Massachusetts-based biopharmaceutical company, has received approval from the US Food and Drug Administration (FDA) to initiate…